Edgewise Therapeutics CSO Alan Russell sells $258k in stock By Investing.com

Alan J. Russell, Chief Scientific Officer and a Director at Edgewise Therapeutics, Inc. (), sold shares of the company’s common stock totaling $258,042 on August 12, 2026. The transactions were primarily conducted to cover statutory tax withholding obligations related to the vesting of his Restricted Stock Units (RSUs), described as a “sell-to-cover” transaction rather than a discretionary sale.

Mr. Russell disposed of a total of 5,901 shares of common stock in multiple transactions. The shares were sold at prices ranging from $43.6759 to $44.46 per share. The stock has surged 212% over the past year and currently trades at $44.17, though InvestingPro analysis suggests the shares are overvalued relative to its Fair Value estimate. According to InvestingPro Tips, the company holds more cash than debt on its balance sheet, maintaining a strong current ratio of 16.24.

The sales followed the vesting of 5,781 shares of common stock and 7,031 shares of common stock, both stemming from previously granted Restricted Stock Units. Additionally, on the same date, Mr. Russell was granted 32,500 new Restricted Stock Units, which will vest in four equal annual installments beginning August 12, 2027. He also received a stock option to purchase 65,000 shares of common stock, with 1/48th of the shares vesting each month starting September 12, 2026, contingent on his continued service to the company.

Following these reported transactions, Mr. Russell directly holds 31,466 shares of Edgewise Therapeutics common stock. He also holds derivative securities, including 32,657 Restricted Stock Units and options to purchase 65,000 shares of common stock.

In other recent news, Edgewise Therapeutics Inc. has completed the sale of its muscular dystrophy business to Servier for a total of up to $2.65 billion. The transaction includes an upfront payment of $1.55 billion, with additional payments contingent on regulatory and commercial milestones. Servier has acquired all rights to sevasemten, along with associated intellectual property and clinical data, and has extended job offers to employees supporting the muscular dystrophy business.

In related developments, investment firms have adjusted their outlook on Edgewise Therapeutics. Oppenheimer initiated coverage on the company with an Outperform rating and set a price target of $51. Guggenheim also raised its price target for Edgewise to $51 from $41, maintaining a Buy rating following the announcement of the Servier deal. Additionally, RBC Capital increased its price target to $59 from $48, citing positive trial data from Edgewise’s HCM drug candidate.

These recent developments reflect significant changes and ongoing interest in Edgewise Therapeutics from the investment community.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.